FDA Warning Letter to La Crema De Rebeca (2026-05-14) — Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
Key takeaway: FDA issued a Warning Letter to La Crema De Rebeca on 2026-05-14 citing: Unapproved New Drugs/Misbranded. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/la-crema-de-rebeca-728782-05142026
Argus analysis
La Crema De Rebeca (MARCS-CMS 728782) received an FDA Warning Letter dated May 14, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Unapproved New Drugs/Misbranded. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 19, 2026.
Unapproved-drug letters cite 21 USC 355 (new drug application requirement) or 21 USC 331(d) (introducing an unapproved new drug into interstate commerce). FDA has increasingly applied these provisions to online sellers of homeopathic products, topical anesthetics, and supplement-adjacent SKUs making unapproved drug claims.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same unapproved new drug category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER La Crema De Rebeca MARCS-CMS 728782 — May 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 728782 Product: Drugs Recipient: La Crema De Rebeca 5508 Apple Orchard Lane Austin , TX 78744 United States lacremaderebeca@gmail.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States May 14, 2026 WARNING LETTER To La Crema De Rebeca: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA has observed that you offer products marketed on your firm's website as skin treatment and skin lightening products, including, but not limited to, “La Crema De Rebeca” for sale in the United States. Additionally, FDA obtained a sample of “La Crema de Rebeca” and has serious safety concerns about this product. FDA confirmed through laboratory analysis that “La Crema de Rebeca” contains high levels of mercury. Applying products that contain mercury to the skin repeatedly can allow mercury to be absorbed into the bloodstream, potentially causing serious and permanent health problems, including kidney damage and neurological damage. Children and pregnant individuals face heightened risks and should avoid exposure to these products. FDA Review Violations were identified and documented during a review of your website https://lacremaderebeca.com/ in April 2026. Based on our review, your product is an unapproved new drug and a misbranded drug under sections 505(a) and 502(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 352(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(a), 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d) and 355(a). This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act Unapproved New Drug Violations The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Based on a review of your website, “La Crema De Rebeca” is a drug under section 201(g)(1…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has La Crema De Rebeca had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for La Crema De Rebeca as of 2026-05-19. Argus ingests new FDA enforcement records daily.
- What FDA violations was La Crema De Rebeca cited for?
- The FDA Warning Letter to La Crema De Rebeca (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to La Crema De Rebeca?
- FDA issued the letter (MARCS-CMS 728782) on 2026-05-14 and posted it publicly on fda.gov on 2026-05-19.
- Is the FDA warning letter to La Crema De Rebeca publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/la-crema-de-rebeca-728782-05142026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to La Crema De Rebeca (2026-05-14) — Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-la-crema-de-rebeca-2026-05-14-unapproved-drug
"FDA Warning Letter to La Crema De Rebeca (2026-05-14) — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-la-crema-de-rebeca-2026-05-14-unapproved-drug.
Argus HQ Research. "FDA Warning Letter to La Crema De Rebeca (2026-05-14) — Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-la-crema-de-rebeca-2026-05-14-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_la_crema_de_rebeca_2026_05_14_unapproved_drug_2026,
title = {FDA Warning Letter to La Crema De Rebeca (2026-05-14) — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-la-crema-de-rebeca-2026-05-14-unapproved-drug},
note = {Accessed: July 13, 2026}
}